Pfizer has initiated a Phase I study for its gastro oesophageal
reflux disease (GORD or GERD using the US spelling) therapy that it
licensed from Kosan Biosciences, in a deal worth up to $250m
(€181m).
In the latest episode of illegal drug trading, a hoard of
unlicensed medicines was seized by the UK Medicines and Healthcare
products Regulatory Agency (MHRA) last week, taken from a London
lock-up containing a stash of various male...
German pharma firm Stada has acquired Russian pharmaceuticals group
Makiz in a deal worth up to €135m, giving the company a sturdy
foothold in the growing Russian market and enhanced in-house
production capacity.
PharmaNet has reported second quarter results that place it back in
the red after it had only just clawed its way back into the black
in the first quarter, following a string of quarterly losses.
In a round-up of motley pharmaceutical services news,
Outsourcing-Pharma takes a look at recent announcements involving
Quintiles, Kenexa, Atos, Catalent Pharma, Patni and Taratec.
GlaxoSmithKline (GSK) has opened the flood gates into the world of
personalised medicine with the world's first ever approved genetic
test, which predicts a life threatening side effect of one of its
antiretroviral drugs.
A statin-based drug candidate is being touted as a potential rival
to Roche's flu vaccine Tamiflu (oseltamivir phosphate) after its
developers revealed yesterday that it showed "superiority"
in the preclinic.
LabTechnologist.com brings you an exclusive interview with Greg
Herrema - president of the Scientific Instruments division of
Thermo Fisher Scientific.
The latest twists and turns in the Inyx Inc. bankruptcy saga
include an attempted power seize by its creditor, fraud allegations
thrown around courtrooms and in the media, the resignation of Inyx'
accountants, and increasing...
MDS Pharma Services has announced it is expanding its development
and regulatory services (DRS) business in Europe while its
bioanalytical operations are still struggling.
Irish researchers have developed a technique that could be used to
deliver controlled amounts of drugs to diseased tissues while
minimising side effects simply by shining light on the target.
Solid-dose specialist Colorcon has hooked up with materials science
firm DataLase to develop a new no-touch on-tablet marking technique
specifically for film-coated tablets, helping to defend branded
tabs from counterfeiting attempts...
GPC Biotech has withdrawn its hotly touted satraplatin New Drug
Application (NDA) for accelerated approval following last week's
less than glowing recommendation to hold off on its approval.
Abraxis BioScience has snapped up another manufacturing plant in
its drive to expand production capabilities, this time announcing
the purchase of Watson Pharmaceuticals' sterile injectables plant.
Sanofi Pasteur, Point Therapeutics, Amira Pharmaceuticals, Elusys
Therapeutics and Chesapeake Pharmaceutical Packaging have all had
people on the move in the world of pharmaceutical manufacturing.
Outsourcing Services Group (OSG) has announced it has sold its
contract manufacturing subsidiary OSG Norwich Pharmaceuticals to a
US private equity firm for an undisclosed amount.
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
